Healthcare, Pharma & Life Sciences

CHOP Names Joseph Mitchell CEO, Succeeding 11-Year Chief Madeline Bell

Image
CHOP Names Joseph Mitchell CEO, Succeeding 11-Year Chief Madeline Bell

Philadelphia – October 01, 2026 -- Children's Hospital of Philadelphia (CHOP) has officially installed Joseph Mitchell, MD, as President and Chief Executive Officer, succeeding Madeline Bell after her nearly four-decade tenure and 11 years as CEO.

Mitchell completes an 18-month transition after joining CHOP as President in April 2025

Mitchell spent the past year and a half working alongside CHOP leadership, clinicians, researchers and community partners ahead of taking full control of the nation's first children's hospital, an institution founded more than 170 years ago.

Baptist Health Care, PAM Health Revise JV to Add 100 Beds

Pensacola, Fla. – October 01, 2026 -- Baptist Health Care and PAM Health have restructured their joint venture, adding 40 acute care beds at Baptist Hospital and building a freestanding 60-bed inpatient rehabilitation hospital at Baptist Medical Park – Nine Mile, pushing Baptist Hospital's total bed count from 279 to 319.

Revised plan scraps original 40-bed rehab unit for larger freestanding facility

The updated agreement replaces a plan first announced in early 2025, which called for a 40-bed inpatient rehabilitation hospital housed within the Henderson Health Center on the Baptist Hospital campus. Under the new structure, PAM Health and Baptist Health Care will instead construct a standalone 60-bed rehabilitation hospital at the Nine Mile campus, freeing the Henderson Health Center space for conversion into a 40-bed acute care unit.

SciBase Secures SEK 57.5M as Rights Issue Fully Subscribed

Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.

Shareholders cover nearly three-quarters of the offering

The subscription period, which ran through 29 September 2026, saw 2,681,085 shares subscribed with the support of subscription rights, equal to roughly SEK 40.2 million, or 69.9 percent of the issue. An additional 133,116 shares were subscribed without subscription rights, adding SEK 2.0 million, or 3.5 percent. In total, 2,814,201 shares were subscribed with and without rights, covering approximately SEK 42.2 million, or 73.4 percent of the SEK 57.5 million target.

Ensera Launches Alliance Network to Streamline Combination Drug-Device Supply

Image
Ensera Launches Alliance Network to Streamline Combination Drug-Device Supply

Dublin – – October 01, 2026 -- Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, uniting device platform and fill-finish specialists to streamline the commercialization of drug-device combination products.

Five specialist firms join the new coordination network

The network currently comprises injector platform providers SHL Medical, Stevanato Group and Ypsomed, alongside fill-finish specialists Argonaut Manufacturing Services and American Injectables. Ensera said it plans to expand the network over time by adding organizations whose capabilities and standards complement existing members.

Lundbeck's VYEPTI Hits 60% Improvement in Phase IV THRIVE Trial

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

Trial enrolled 164 adults who had failed one prior CGRP preventive treatment

The 24-week, open-label, multicenter trial (NCT06701526) was conducted in the United States and enrolled 164 adults with at least eight monthly migraine days who had previously used either a subcutaneous anti-CGRP monoclonal antibody or a preventive gepant, but had not received eptinezumab. Participants started on 100 mg of eptinezumab, escalating to 300 mg at week 12, with 147 receiving both infusions; 84% (138/164) completed the trial.

AlignRx Spotlights PBM Dominance Squeezing Community Pharmacies

Image
AlignRx Spotlights PBM Dominance Squeezing Community Pharmacies

Los Angeles – October 01, 2026 -- Three pharmacy benefit managers—CVS Caremark, Optum Rx, and Express Scripts—processed roughly 80% of U.S. prescription claims last year, a concentration that AlignRx says is squeezing independent pharmacies out of the market. The nation's largest independently owned Pharmacy Services Administrative Organization (PSAO) is the subject of a forthcoming feature on the public television series All Access with Andy Garcia, which examines the reimbursement pressures facing community pharmacies nationwide.

Vertically integrated PBMs leave pharmacies reimbursed below drug cost

The feature details how market consolidation among the three dominant PBMs has created a vertically integrated system in which patients face higher out-of-pocket costs and reduced choice. Community pharmacies, AlignRx says, are often reimbursed less than the cost of the medication they dispense, straining their ability to stay open.

Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Image
Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.

Fresenius consolidates control after four-year partnership

Fresenius first acquired a 55% majority stake in mAbxience in August 2022 and has consolidated the business since then. The deal closes out that ownership structure, placing mAbxience's biosimilars platform entirely within Fresenius Kabi's Biopharma division, which spans development, manufacturing and commercialization.

Emerald Clinical Trials Names Michael Stibilj CEO as CRO Scales APAC Platform

Image
Emerald Clinical Trials Names Michael Stibilj CEO as CRO Scales APAC Platform

Singapore – October 01, 2026 -- Emerald Clinical Trials has appointed Michael Stibilj as Chief Executive Officer, effective October 01, 2026, tasking the 30-year CRO veteran with leading the next phase of growth for a platform that now spans more than 1,000 professionals across 40-plus countries and 70-plus locations.

Stibilj joins from six years as Chief Operating Officer at Novotech

Before Novotech, Stibilj served three years as CEO of PPC Group and spent 22 years at IQVIA in regional and global leadership roles, with operational experience across China, Singapore and Australia.

Appointment follows the acquisition of Hongyi Clinical Development Services

The deal combined Emerald with Hongyi to create a clinical development platform supporting sponsors from first-in-human trials through post-marketing across China, Asia-Pacific, Europe and the Americas.

Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Image
Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Indianapolis – – October 01, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Foundayo meets non-inferiority bar on major cardiovascular events

Among 2,749 participants randomized across 16 countries including the U.S., Germany, India, Brazil and South Korea, Foundayo showed a 16% lower risk of MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) versus insulin glargine, with a hazard ratio of 0.84 (95.0% CI: 0.59 to 1.20), meeting the prespecified non-inferiority threshold. The risk of MACE-3 (cardiovascular death, heart attack or stroke) was 23% lower (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13).

Halozyme Names Ex-Incyte Commercial Chief Jim Daly to Board

Image
Halozyme Names Ex-Incyte Commercial Chief Jim Daly to Board

San Diego – October 01, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.

Daly rejoins board after prior tenure, bringing three decades of launch experience

Daly previously served on Halozyme's board and has held senior commercial leadership roles at Incyte Corporation, Amgen and Glaxo Wellcome/GlaxoSmithKline. He was Executive Vice President and Chief Commercial Officer of Incyte from 2012 to 2015, following a decade at Amgen where he most recently served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier, he spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including as Senior Vice President and General Manager of the U.S. respiratory business.